Article: Acadia pairs up: Acadia Pharmaceuticals.(Monday, May 4)

Acadia Pairs Up: Acadia Pharmaceuticals signed a deal worth up to $395 million to bring its experimental Parkinson's disease psychosis drug to market, the company said.

Shares of Acadia spiked on the news, closing up 134 percent at $2.34. Acadia is traded under the symbol ACAD on the Nasdaq.

San Diego-based Acadia will partner with Canadian company Biovail to help fund its research operations, Under the agreement, Acadia will receive $30 million upfront and up to an additional $365 million if it meets certain benchmarks, including ...

Related newspaper, magazine, and journal articles:

 
 
Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 80 million articles! Access over 6,500 publications with a FREE trial!